Last updated: September 27, 2026
ecutive summary: Methamphetamine hydrochloride is a mature, low-volume controlled-substance market dominated by the branded product Desoxyn and limited generic supply. Its FDA-approved uses are ADHD and short-term adjunctive treatment of exogenous obesity, but prescribing is constrained by abuse potential, Schedule II controls, stigma, and competition from amphetamine, methylphenidate, lisdexamfetamine, and newer nonstimulants. The molecule has no meaningful remaining composition-of-matter patent protection. Commercial value depends on manufacturing continuity, DEA quota access, regulatory compliance, and scarcity pricing rather than patent exclusivity. Standalone product revenue is not publicly disclosed, so the financial trajectory is best assessed through market structure, supply constraints, and substitution risk.
Methamphetamine Hydrochloride Market Dynamics, Patent Status, and Financial Trajectory
What is the current market position of methamphetamine hydrochloride?
Methamphetamine hydrochloride is marketed in the United States primarily as Desoxyn, a 5 mg immediate-release tablet. The product is approved for attention-deficit/hyperactivity disorder and as a short-term adjunct in weight reduction for patients whose obesity is not adequately managed by diet and other interventions.[1]
The market is small relative to other prescription stimulants. Methamphetamine hydrochloride competes with:
- Mixed amphetamine salts, including Adderall and authorized generics
- Lisdexamfetamine, marketed as Vyvanse and available in generic form
- Methylphenidate products, including Ritalin, Concerta, and generics
- Dexmethylphenidate, including Focalin
- Atomoxetine, viloxazine, and extended-release guanfacine
- Obesity medicines, including GLP-1 receptor agonists and other anti-obesity therapies
Methamphetamine hydrochloride has pharmacologic advantages in potency and oral bioavailability, but these attributes do not translate into broad commercial adoption. Prescribers generally reserve the product for selected patients because of its high abuse liability, diversion concerns, and the availability of alternatives with broader clinical use and stronger payer familiarity.
Who manufactures and markets Desoxyn?
Desoxyn has changed commercial ownership and distribution arrangements over its long history. The current FDA labeling identifies the product through its approved New Drug Application, NDA 005378.[1] Commercial responsibility has been associated with specialty pharmaceutical companies rather than large-volume primary-care manufacturers.
The market structure has several characteristics:
| Market factor |
Effect on methamphetamine hydrochloride |
| Product type |
Immediate-release 5 mg tablet |
| Regulatory class |
Schedule II controlled substance |
| Primary U.S. product |
Desoxyn |
| FDA pathway |
Legacy NDA |
| Generic competition |
Limited and commercially inconsistent |
| Patent dependence |
Minimal |
| Supply dependence |
High |
| Prescriber base |
Narrow |
| Reimbursement leverage |
Weak relative to mainstream ADHD products |
| Revenue disclosure |
No standalone public reporting |
A company can maintain commercial value without patent protection if it controls manufacturing, distribution, DEA quota, and regulatory infrastructure. Those barriers are operational rather than technological.
What patents protect methamphetamine hydrochloride?
No commercially important composition-of-matter patent protects methamphetamine hydrochloride in the United States. The active pharmaceutical ingredient is an old small molecule, and the original patent term expired many decades ago.
The relevant intellectual-property position is therefore limited to potential:
- Historical formulation patents
- Manufacturing-process patents
- Packaging or stability claims
- Product-specific regulatory exclusivity, if any
- Trademarks and trade dress
- Supply, distribution, and controlled-substance compliance capabilities
These rights do not create a durable patent moat comparable to a modern branded ADHD medicine or an innovative extended-release delivery system.
What is the Orange Book status of Desoxyn?
The FDA Orange Book is the controlling source for current patent and exclusivity listings. Desoxyn’s commercial value does not appear to depend on an unexpired, high-value Orange Book patent estate. The product’s original approval dates to the early era of U.S. stimulant regulation, and any historical patent protection has expired.[1,2]
The practical implication is that a qualifying generic applicant would not face a modern composition-of-matter patent barrier. A Paragraph IV certification could still be relevant if an unexpired listed patent existed, but the principal barriers for this product are likely manufacturing, controlled-substance compliance, market size, and supply economics.
When does methamphetamine hydrochloride lose exclusivity?
Methamphetamine hydrochloride lost meaningful patent exclusivity long ago. Desoxyn does not have the exclusivity profile of a recently approved branded drug.
| Exclusivity category |
Status |
| Original molecule patent |
Expired |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
No current commercial significance |
| Orphan-drug exclusivity |
Not applicable |
| Modern formulation exclusivity |
No material public market evidence |
| FDA market exclusivity |
Not a current strategic barrier |
| Trademark protection |
Potentially remains, but does not block generic active ingredient supply |
FDA regulatory exclusivity and patent protection are separate. Even where no patent blocks approval, a generic applicant still must establish pharmaceutical equivalence, bioequivalence, manufacturing quality, and compliance with controlled-substance requirements.
How many patents cover methamphetamine hydrochloride?
The number of historical patents associated with methamphetamine hydrochloride is not a useful measure of current market protection. The commercially relevant question is how many unexpired, enforceable U.S. patents are listed against the marketed product. The answer is effectively none of strategic importance based on the product’s age and legacy regulatory status.
Potential process patents could affect a particular manufacturer, but they would not normally prevent all competing production. A process patent also would not restore exclusivity to the molecule itself if alternative manufacturing routes were available.
What FDA regulatory status applies to methamphetamine hydrochloride?
Methamphetamine hydrochloride is an FDA-approved prescription drug and a Schedule II controlled substance under the Controlled Substances Act.[1,3] The product carries boxed-warning-level risks associated with abuse, misuse, addiction, and serious cardiovascular and psychiatric effects.
Key regulatory characteristics include:
- Prescription-only dispensing
- Schedule II controls
- No refills under federal law
- Electronic or written controlled-substance prescribing requirements
- Exposure to DEA production quotas
- Heightened scrutiny of suspicious orders and distribution
- Required monitoring for misuse, diversion, and addiction
- Restrictions on promotional claims outside the approved label
The obesity indication is commercially less relevant than the ADHD indication. Modern obesity pharmacotherapy has moved toward chronic treatment with GLP-1 receptor agonists and other agents. A Schedule II stimulant labeled for short-term weight reduction has little competitive positioning against those products.
What formulation patents protect Desoxyn?
Desoxyn is an immediate-release tablet rather than a differentiated extended-release, transdermal, or abuse-deterrent delivery system. That limits opportunities to create formulation-based exclusivity.
A new formulation could theoretically support patent protection if it produced a novel and nonobvious pharmacokinetic, abuse-deterrent, or delivery profile. No widely commercialized next-generation methamphetamine hydrochloride formulation has established a meaningful market position.
The absence of an extended-release or abuse-deterrent franchise reduces lifecycle-management potential. In ADHD, competing products have built commercial value through duration, dosing convenience, pediatric formulations, and lower abuse potential. Desoxyn has limited differentiation on those dimensions.
What is the generic competition and Paragraph IV risk?
Generic competition is legally possible because the active ingredient is long off patent. The commercial question is whether the market is large enough to support an ANDA applicant.
A generic entrant would face:
- A small addressable patient population.
- Controlled-substance registration and quota requirements.
- API sourcing and quality-control obligations.
- Limited pharmacy stocking.
- Prescriber reluctance.
- Potentially thin reimbursement economics.
- Price erosion if several suppliers enter.
- Supply volatility if manufacturers reduce production.
A Paragraph IV challenge would have limited strategic value unless it targeted an unexpired product or process patent. The stronger entry strategy would likely be a standard ANDA pathway or a commercial supply arrangement with a qualified controlled-substance manufacturer.
Generic launch scenarios fall into three categories:
| Scenario |
Market effect |
| No new entrant |
Incumbent retains scarcity-based pricing and distribution control |
| One generic entrant |
Moderate price pressure, improved pharmacy access |
| Multiple generic entrants |
Rapid price erosion and reduced commercial incentive to maintain supply |
The third scenario is less likely than in high-volume generic markets because methamphetamine hydrochloride demand is narrow and regulatory overhead is high.
Which companies are challenging the Desoxyn market?
The principal competitive threat does not come from patent challengers. It comes from therapeutic substitutes.
ADHD competitors
Amphetamine and methylphenidate products dominate the ADHD stimulant market. Their advantages include extensive clinical familiarity, multiple dosage strengths, extended-release options, established payer coverage, and broader generic availability.
Nonstimulant competitors
Atomoxetine, viloxazine, and guanfacine offer alternatives for patients with abuse risk, cardiovascular concerns, or intolerance to stimulants. These products reduce the addressable population for methamphetamine hydrochloride.
Obesity competitors
GLP-1 and related anti-obesity drugs have changed the economic profile of weight-management treatment. Their chronic-use model and large commercial investment make Desoxyn’s short-term obesity indication strategically marginal.
How strong is the patent estate for methamphetamine hydrochloride?
The patent estate is weak. Its strength is best characterized as low for exclusionary rights and moderate for operational barriers.
| Estate component |
Strength |
| Molecule patent |
None of commercial relevance |
| Core product patent |
Weak or expired |
| Formulation protection |
Limited |
| Method-of-use protection |
Limited and old |
| Manufacturing know-how |
Potentially meaningful |
| Controlled-substance infrastructure |
Meaningful |
| Trademark and brand recognition |
Moderate within a narrow niche |
| Distribution relationships |
Potentially meaningful |
| Regulatory compliance capability |
High operational importance |
This is a business with an operational moat, not a patent moat. A manufacturer with reliable API access, DEA quota, compliant facilities, and disciplined distribution can preserve value even without exclusivity.
What is the financial trajectory for methamphetamine hydrochloride?
No major manufacturer publicly reports standalone global revenue for methamphetamine hydrochloride. Desoxyn revenue is generally embedded within broader specialty-pharmaceutical or controlled-substance portfolios. Public filings therefore do not support a precise product-level revenue history.
The financial trajectory has four likely phases:
Historical phase: protected and branded
The product benefited from legacy brand positioning before generic-drug economics and modern ADHD competition reshaped the market.
Mature phase: low-volume branded supply
The product moved into a niche market with limited prescribing and a small patient base. Revenue became dependent on price, supply continuity, and distribution rather than volume growth.
Current phase: scarcity-supported economics
Revenue can remain stable or rise despite low prescription volume if supply is constrained and the product retains premium pricing. This is not equivalent to durable market growth. A single supply interruption or generic launch could materially reduce value.
Forward phase: operational-risk exposure
The most likely long-term pattern is low-to-modest nominal revenue with high volatility. Growth from patient volume is unlikely. Downside risk comes from generic entry, payer substitution, regulatory intervention, manufacturing disruption, or a further shift toward nonstimulant and extended-release therapies.
A simple commercial model is:
Revenue = treated patients × annual units per patient × net price
For methamphetamine hydrochloride, treated-patient growth is constrained, annual volume is modest, and net price can be influenced by scarcity. That leaves net price and supply continuity as the main financial variables.
What revenue exposure and investment risks matter most?
The product is unlikely to represent material revenue exposure for a diversified pharmaceutical company. It can matter disproportionately to a small specialty company because a narrow product portfolio magnifies:
- Loss of a single manufacturing site
- DEA quota reductions
- API shortages
- Product recalls
- Contract-manufacturing failure
- Generic entry
- Pricing scrutiny
- Distributor termination
- Compliance findings
The principal investment risk is concentration. A product with low absolute sales can still be economically important if it accounts for a large share of a company’s specialty portfolio.
What patent litigation or settlements affect methamphetamine hydrochloride?
There is no widely recognized current patent litigation campaign comparable to litigation involving major branded drugs. Because the molecule is old and the product has limited patent protection, litigation exposure is more likely to involve:
- ANDA approval disputes
- Manufacturing or quality claims
- Controlled-substance distribution
- False or misleading promotion
- Contract and supply disagreements
- Product liability
Settlement agreements involving Paragraph IV challenges are not the central commercial feature of this market. A settlement could arise if a generic applicant identifies a listed patent or other product-specific right, but the economic significance would likely be limited by the market’s small size.
How does methamphetamine hydrochloride compare with Adderall and Vyvanse?
| Attribute |
Methamphetamine HCl |
Mixed amphetamine salts |
Lisdexamfetamine |
| Main U.S. brand |
Desoxyn |
Adderall |
Vyvanse |
| Release profile |
Immediate release |
Immediate and extended release |
Long-acting prodrug |
| Controlled status |
Schedule II |
Schedule II |
Schedule II |
| Prescriber familiarity |
Low |
High |
High |
| Generic depth |
Limited |
Broad |
Increasing |
| Abuse concerns |
High |
High |
Still present, with prodrug design |
| Patent value |
Minimal |
Historical and formulation-specific |
Historically stronger formulation protection |
| ADHD market position |
Niche |
Large |
Large |
| Commercial growth |
Limited |
Mature |
Larger modern franchise |
Desoxyn’s principal weakness is not the absence of efficacy. It is the combination of limited differentiation, high controlled-substance risk, and strong substitution from established products.
Key takeaways
- Methamphetamine hydrochloride is an FDA-approved Schedule II stimulant marketed primarily as Desoxyn.
- The active ingredient has no meaningful remaining composition-of-matter patent protection.
- Current value depends on supply, DEA quota, manufacturing compliance, and distribution rather than exclusivity.
- Desoxyn operates in a narrow ADHD niche and has little strategic relevance in modern obesity pharmacotherapy.
- Generic entry is legally feasible, but market size and controlled-substance requirements limit economic attractiveness.
- No standalone product revenue is publicly disclosed.
- Financial performance is likely to remain low-volume, supply-sensitive, and vulnerable to substitution.
- The patent estate is weak; the operational barrier is stronger than the intellectual-property barrier.
- The main competitive threats are amphetamine, methylphenidate, lisdexamfetamine, and nonstimulant ADHD therapies.
- The most material downside risks are generic launch, supply interruption, regulatory action, and portfolio concentration.
FAQs
Is methamphetamine hydrochloride still sold as Desoxyn?
Yes. Desoxyn is the principal U.S. marketed product containing methamphetamine hydrochloride, subject to FDA approval and Schedule II controls.[1]
Can a generic version of methamphetamine hydrochloride launch?
Yes, in principle. A generic applicant would need to satisfy FDA ANDA requirements and obtain the necessary DEA registrations and production quota.
Does Desoxyn have an unexpired patent?
No commercially important composition-of-matter patent remains. Any current product-specific protection must be verified through the FDA Orange Book and related regulatory records.
Is methamphetamine hydrochloride used for obesity treatment?
The FDA label includes short-term adjunctive treatment of exogenous obesity, but the indication has limited commercial importance relative to modern chronic obesity medicines.[1]
What is the biggest commercial risk for Desoxyn?
The largest risks are substitution by other ADHD medicines, generic entry, supply disruption, and loss of manufacturing or controlled-substance distribution capability.
References
- U.S. Food and Drug Administration. (n.d.). Desoxyn (methamphetamine hydrochloride) tablets: Prescribing information. FDA.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
- U.S. Drug Enforcement Administration. (n.d.). Controlled substance schedules. U.S. Department of Justice.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.
